{"id":585578,"date":"2026-07-02T00:00:00","date_gmt":"2026-07-02T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/conccg0006-2026-biopharma-myasthenia-gravis-geography-focus-china-china-in-depth-myasthenia-gravis\/"},"modified":"2026-07-02T00:00:00","modified_gmt":"2026-07-02T00:00:00","slug":"conccg0006-2026-biopharma-myasthenia-gravis-geography-focus-china-china-in-depth-myasthenia-gravis","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/conccg0006-2026-biopharma-myasthenia-gravis-geography-focus-china-china-in-depth-myasthenia-gravis\/","title":{"rendered":"Myasthenia Gravis &#8211; Geography Focus: China &#8211; China In-Depth: Myasthenia Gravis"},"content":{"rendered":"<p>China\u2019s myasthenia gravis (<abbr title=\"myasthenia gravis\">MG<\/abbr>) market is transitioning from long-standing symptomatic regimens toward a more structured mix of targeted therapies that increasingly shape treatment pathways. Traditional oral options, including acetyl cholinesterase inhibitors and corticosteroids, remain foundational for early management, but the expanding presence of targeted categories is redefining clinical decision-making. Complement inhibitors\u2014such as AstraZeneca\u2019s eculizumab and ravulizumab, and <abbr title=\"Union Chimique Belge\">UCB<\/abbr>\u2019s zilucoplan; and <abbr title=\"neonatal Fc receptor\">FcRn<\/abbr> antagonists\u2014such as Zai Lab\u2019s efgartigimod alfa,\u00a0and <abbr title=\"Union Chimique Belge\">UCB<\/abbr>\u2019s rozanolixizumab\u2014 have broadened specialist choices. In parallel, <abbr title=\"B-cell-activating factor\">BAFF<\/abbr>\/<abbr title=\"a proliferation-inducing ligand\">APRIL<\/abbr> inhibitors such as RemeGen\u2019s telitacicept are further diversifying the treatment landscape, influencing sequencing, duration of use, and siteofcare preferences. Despite these advances, a notable\u00a0unmet need persists in ocular <abbr title=\"myasthenia gravis\">MG<\/abbr>, where treatment options remain limited. Recent approvals of\u00a0Inebilizumab (Hansoh Pharma\u2019s Uplizna, March 2026) and nipocalimab (Johnson &#038; Johnson\u2019s Imaavy,\u00a0May 2026) represent key progress in <abbr title=\"myasthenia gravis\">MG<\/abbr> treatment. Meanwhile, late-phase programs, including Regeneron\u2019s cemdisiran (monotherapy and FDC combination), AstraZeneca\u2019s gefurulimab, Novartis\u2019s iptacopan, and remibrutinib and others, signal continued diversification in targeted approaches and potential expansion of choices for generalized <abbr title=\"myasthenia gravis\">MG<\/abbr>. This report provides a comprehensive evaluation of China\u2019s <abbr title=\"myasthenia gravis\">MG<\/abbr> therapy landscape, examining treatment patterns, unmet needs, and commercial outlook for current and emerging therapies, and evaluates how evolving pricing, coverage, and regulatory reforms may shape future launch and uptake dynamics.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>How large is China\u2019s drug-treatable <abbr title=\"myasthenia gravis\">MG<\/abbr> population, and how will drug-treatment rates change during the forecast period?<\/li>\n<li>What are the interviewed experts\u2019 insights into current treatment options?<\/li>\n<li>What are the key unmet needs in the management of <abbr title=\"myasthenia gravis\">MG<\/abbr>?<\/li>\n<li>How will the <abbr title=\"myasthenia gravis\">MG<\/abbr> therapy market evolve over the next 10 years?<\/li>\n<li>What are the drivers and constraints in the Chinese <abbr title=\"myasthenia gravis\">MG<\/abbr> market, and how will the market evolve through 2035?<\/li>\n<li>How large is China\u2019s drug-treatable <abbr title=\"myasthenia gravis\">MG<\/abbr> population, and how will drug-treatment rates change during the forecast period?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong>\u00b7<\/p>\n<p>China In-Depth offers comprehensive market intelligence with world-class epidemiology, insight into the China-specific market access landscape, current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:<\/p>\n<ul class=\"round-bullets\">\n<li>Optimize your long-term disease and development strategy in China.<\/li>\n<li>Quantify market potential for your pipeline assets and those of your competitors.<\/li>\n<li>Understand current treatment paradigms, the complex access and reimbursement environment, and the current and future therapeutic landscape.<\/li>\n<\/ul>\n<p><strong>Release date: <\/strong>July 2026<\/p>\n<p><strong>Geography: <\/strong>China (urban \/ rural)<\/p>\n<p><strong>Primary research: <\/strong>Qualitative and quantitative insights driven by 5 thought-leader interviews and surveys with 50 neurologists in China<\/p>\n<p><strong>Epidemiology: <\/strong>Diagnosed prevalence of myasthenia gravis patients in urban versus rural China; clinically relevant and market-relevant drug-treatable populations<\/p>\n<p><strong>Forecast: <\/strong>10-year, annualized, drug-level sales and patient share of key myasthenia gravis therapies through 2035, based on primary and secondary market research to formulate bottom-up assumptions<\/p>\n<p><strong>Drug treatments: <\/strong>Coverage of key current and late-phase emerging therapies<\/p>\n<p><strong>Custom<\/strong><strong> drug modeler: <\/strong>Integrated tool to input customized forecast assumptions (e.g., launch date, price)<\/p>\n","protected":false},"template":"","class_list":["post-585578","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-neurology","biopharma-product-china-in-depth","biopharma-geography-china","biopharma-geography-us","biopharma-date-2609"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/585578","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=585578"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}